聚焦AKT：当前的治疗挑战。
Spotlight on AKT: Current Therapeutic Challenges.
作者信息
Landel Ina, Quambusch Lena, Depta Laura, Rauh Daniel
机构信息
Faculty of Chemistry and Chemical Biology, TU Dortmund University and Drug Discovery Hub Dortmund (DDHD), Zentrum für Wirkstoffforschung (ZIW), Otto-Hahn-Strasse 4a, 44227 Dortmund, Germany.
出版信息
ACS Med Chem Lett. 2020 Mar 12;11(3):225-227. doi: 10.1021/acsmedchemlett.9b00548.
Abstract
The protein kinase B (Akt) exemplifies an important switch of cell death and survival within the PI3K/Akt signaling pathway, which renders Akt a valuable target in diseases such as cancer. Herein, we give a short overview of clinical applications involving Akt, outline promising and innovative approaches to investigate the role of this kinase in diseases, and highlight the current challenges that require thorough investigation to set the groundwork for successful therapeutic strategies.
摘要
蛋白激酶B（Akt）是PI3K/Akt信号通路中细胞死亡和存活的重要开关，这使得Akt成为癌症等疾病中有价值的靶点。在此，我们简要概述涉及Akt的临床应用，概述研究该激酶在疾病中作用的有前景和创新性方法，并强调当前需要深入研究以奠定成功治疗策略基础的挑战。
相似文献
1
Spotlight on AKT: Current Therapeutic Challenges.聚焦AKT：当前的治疗挑战。
ACS Med Chem Lett. 2020 Mar 12;11(3):225-227. doi: 10.1021/acsmedchemlett.9b00548.
2
PI3K/AKT/mTOR signaling pathway as a therapeutic target for ovarian cancer.PI3K/AKT/mTOR信号通路作为卵巢癌的治疗靶点
Arch Gynecol Obstet. 2014 Dec;290(6):1067-78. doi: 10.1007/s00404-014-3377-3. Epub 2014 Aug 3.
3
PI3K signaling in cancer: beyond AKT.癌症中的PI3K信号传导：超越AKT
Curr Opin Cell Biol. 2017 Apr;45:62-71. doi: 10.1016/j.ceb.2017.02.007. Epub 2017 Mar 24.
4
Role of the PI3K/AKT/mTOR signaling pathway in ovarian cancer: Biological and therapeutic significance.PI3K/AKT/mTOR 信号通路在卵巢癌中的作用：生物学和治疗意义。
Semin Cancer Biol. 2019 Dec;59:147-160. doi: 10.1016/j.semcancer.2019.05.012. Epub 2019 May 22.
5
Therapeutic Potential of Autophagy in Glioblastoma Treatment With Phosphoinositide 3-Kinase/Protein Kinase B/Mammalian Target of Rapamycin Signaling Pathway Inhibitors.自噬在胶质母细胞瘤治疗中与磷脂酰肌醇3激酶/蛋白激酶B/雷帕霉素哺乳动物靶标信号通路抑制剂联用的治疗潜力
Front Oncol. 2020 Oct 2;10:572904. doi: 10.3389/fonc.2020.572904. eCollection 2020.
6
The Current Status and Future Role of the Phosphoinositide 3 Kinase/AKT Signaling Pathway in Urothelial Cancer: An Old Pathway in the New Immunotherapy Era.磷酸肌醇 3 激酶/蛋白激酶 B 信号通路在尿路上皮癌中的现状和未来作用：免疫治疗新时代的老通路。
Clin Genitourin Cancer. 2018 Apr;16(2):e269-e276. doi: 10.1016/j.clgc.2017.10.011. Epub 2017 Nov 3.
7
Inhibition of PI3K/Akt signaling: an emerging paradigm for targeted cancer therapy.抑制PI3K/Akt信号传导：一种新兴的靶向癌症治疗模式。
Curr Med Chem Anticancer Agents. 2005 Nov;5(6):575-89. doi: 10.2174/156801105774574649.
8
New insights into Notch1 regulation of the PI3K-AKT-mTOR1 signaling axis: targeted therapy of γ-secretase inhibitor resistant T-cell acute lymphoblastic leukemia.深入了解 Notch1 对 PI3K-AKT-mTOR1 信号轴的调控：γ-分泌酶抑制剂耐药 T 细胞急性淋巴细胞白血病的靶向治疗。
Cell Signal. 2014 Jan;26(1):149-61. doi: 10.1016/j.cellsig.2013.09.021. Epub 2013 Oct 16.
9
PI3K/ Akt/ mTOR Pathway as a Therapeutic Target for Colorectal Cancer: A Review of Preclinical and Clinical Evidence.PI3K/Akt/mTOR 通路作为结直肠癌的治疗靶点：临床前和临床证据的综述。
Curr Drug Targets. 2019;20(12):1217-1226. doi: 10.2174/1389450120666190618123846.
10
The Potential Value of the PI3K/Akt/mTOR Signaling Pathway for Assessing Prognosis in Cervical Cancer and as a Target for Therapy.PI3K/Akt/mTOR 信号通路在评估宫颈癌预后及作为治疗靶点中的潜在价值。
J Cell Biochem. 2017 Dec;118(12):4163-4169. doi: 10.1002/jcb.26118. Epub 2017 Jun 22.
引用本文的文献
1
The Precision-Guided Use of PI3K Pathway Inhibitors for the Treatment of Solid Malignancies.PI3K 通路抑制剂在实体恶性肿瘤治疗中的精准应用
Biomedicines. 2025 May 28;13(6):1319. doi: 10.3390/biomedicines13061319.
2
AKT kinases as therapeutic targets.AKT 激酶作为治疗靶点。
J Exp Clin Cancer Res. 2024 Nov 29;43(1):313. doi: 10.1186/s13046-024-03207-4.
3
GPNMB is a novel binding partner of FGFR1 that affects tumorigenic potential through AKT phosphorylation in TNBC.GPNMB是FGFR1的一种新型结合伴侣，它通过TNBC中的AKT磷酸化影响致瘤潜能。
Cancer Sci. 2025 Feb;116(2):432-443. doi: 10.1111/cas.16419. Epub 2024 Nov 28.
4
Vertical targeting of the PI3K/AKT pathway at multiple points is synergistic and effective for non-Hodgkin lymphoma.在多个位点对PI3K/AKT通路进行垂直靶向治疗对非霍奇金淋巴瘤具有协同作用且效果显著。
Exp Hematol Oncol. 2024 Nov 1;13(1):108. doi: 10.1186/s40164-024-00568-6.
5
Overcoming Cancer Drug Resistance with Nanoparticle Strategies for Key Protein Inhibition.利用纳米颗粒策略抑制关键蛋白克服癌症药物耐药性。
Molecules. 2024 Aug 23;29(17):3994. doi: 10.3390/molecules29173994.
6
From Crypts to Cancer: A Holistic Perspective on Colorectal Carcinogenesis and Therapeutic Strategies.从隐窝到癌症：结直肠癌发生和治疗策略的整体观点。
Int J Mol Sci. 2024 Aug 30;25(17):9463. doi: 10.3390/ijms25179463.
7
CRLF1 bridges AKT and mTORC2 through SIN1 to inhibit pyroptosis and enhance chemo-resistance in ovarian cancer.CRLF1 通过 SIN1 桥接 AKT 和 mTORC2 抑制卵巢癌细胞焦亡并增强化疗耐药性。
Cell Death Dis. 2024 Sep 10;15(9):662. doi: 10.1038/s41419-024-07035-4.
8
A new method for network bioinformatics identifies novel drug targets for mucinous ovarian carcinoma.一种用于网络生物信息学的新方法鉴定出了黏液性卵巢癌的新药物靶点。
NAR Genom Bioinform. 2024 Aug 24;6(3):lqae096. doi: 10.1093/nargab/lqae096. eCollection 2024 Sep.
9
A conserved role for AKT in the replication of emerging flaviviruses in vertebrates and vectors.AKT 在脊椎动物和媒介中新兴黄病毒复制中的保守作用。
Virus Res. 2024 Oct;348:199447. doi: 10.1016/j.virusres.2024.199447. Epub 2024 Aug 9.
10
The value of protein allostery in rational anticancer drug design: an update.蛋白质变构在合理抗癌药物设计中的价值：更新。
Expert Opin Drug Discov. 2024 Sep;19(9):1071-1085. doi: 10.1080/17460441.2024.2384467. Epub 2024 Jul 28.
本文引用的文献
1
Covalent-Allosteric Inhibitors to Achieve Akt Isoform-Selectivity.实现 Akt 同工型选择性的共价变构抑制剂。
Angew Chem Int Ed Engl. 2019 Dec 19;58(52):18823-18829. doi: 10.1002/anie.201909857. Epub 2019 Nov 8.
2
Phase II trial of AKT inhibitor MK-2206 in patients with advanced breast cancer who have tumors with PIK3CA or AKT mutations, and/or PTEN loss/PTEN mutation.PIK3CA 或 AKT 突变和/或 PTEN 缺失/PTEN 突变的晚期乳腺癌患者中 AKT 抑制剂 MK-2206 的 II 期临床试验。
Breast Cancer Res. 2019 Jul 5;21(1):78. doi: 10.1186/s13058-019-1154-8.
3
First evidence of a therapeutic effect of miransertib in a teenager with Proteus syndrome and ovarian carcinoma.首例米哚妥林治疗青少年 Proteus 综合征合并卵巢癌的疗效证据。
Am J Med Genet A. 2019 Jul;179(7):1319-1324. doi: 10.1002/ajmg.a.61160. Epub 2019 May 6.
4
Structural and chemical insights into the covalent-allosteric inhibition of the protein kinase Akt.对蛋白激酶Akt共价变构抑制的结构与化学见解。
Chem Sci. 2019 Feb 13;10(12):3573-3585. doi: 10.1039/c8sc05212c. eCollection 2019 Mar 28.
5
Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in -Mutant Pancreatic and Colorectal Cancer.在 - 突变型胰腺和结直肠癌中，共价变构 AKT 抑制剂 Borussertib 与 Trametinib 联合的临床前疗效。
Cancer Res. 2019 May 1;79(9):2367-2378. doi: 10.1158/0008-5472.CAN-18-2861. Epub 2019 Mar 11.
6
The Akt pathway in oncology therapy and beyond (Review).肿瘤治疗领域中 Akt 通路的研究进展及其相关应用（综述）。
Int J Oncol. 2018 Dec;53(6):2319-2331. doi: 10.3892/ijo.2018.4597. Epub 2018 Oct 16.
7
AKT Inhibition in Solid Tumors With AKT1 Mutations.对携带AKT1突变的实体瘤进行AKT抑制
J Clin Oncol. 2017 Jul 10;35(20):2251-2259. doi: 10.1200/JCO.2017.73.0143. Epub 2017 May 10.
8
A First-in-Human Phase I Study of the ATP-Competitive AKT Inhibitor Ipatasertib Demonstrates Robust and Safe Targeting of AKT in Patients with Solid Tumors.ATP竞争性AKT抑制剂ipatasertib的首次人体I期研究表明，在实体瘤患者中对AKT进行了有效且安全的靶向治疗。
Cancer Discov. 2017 Jan;7(1):102-113. doi: 10.1158/2159-8290.CD-16-0512. Epub 2016 Nov 21.
9
AKT in cancer: new molecular insights and advances in drug development.AKT与癌症：药物研发中的新分子见解与进展
Br J Clin Pharmacol. 2016 Oct;82(4):943-56. doi: 10.1111/bcp.13021. Epub 2016 Jun 27.
10
Akt inhibitors in cancer treatment: The long journey from drug discovery to clinical use (Review).Akt抑制剂在癌症治疗中的应用：从药物发现到临床应用的漫长历程（综述）
Int J Oncol. 2016 Mar;48(3):869-85. doi: 10.3892/ijo.2015.3306. Epub 2015 Dec 24.
Zotero 插件